Can we identify individuals with an ALPL variant in adults with persistent hypophosphatasaemia? by Tornero, C. et al.
RESEARCH Open Access
Can we identify individuals with an ALPL
variant in adults with persistent
hypophosphatasaemia?
C. Tornero1*, V. Navarro-Compán1, J. A. Tenorio2,3, S. García-Carazo1, A. Buño4, I. Monjo1, C. Plasencia-Rodriguez1,
J. M. Iturzaeta4, P. Lapunzina2,3, K. E. Heath2,3,5, A. Balsa1 and P. Aguado1
Abstract
Background: Hypophosphatasia (HPP) is an inborn error of metabolism characterized by low levels of serum
alkaline phosphatase (ALP). Scarce evidence exists about features that should signal the potential association
between hypophosphatasaemia and HPP in adults. The aim of this study is to estimate the prevalence of ALPL
variants in subjects with persistent hypophosphatasaemia and determine the associated clinical and laboratory
features. For this cross-sectional study, laboratory records of 386,353 subjects were screened by measurement of
ALP activity. A total of 85 (0.18%) subjects with persistent hypophosphatasaemia (≥2 serum alkaline phosphatase–
ALP–measurements ≤35 IU/L and none > 45 IU/L) were included (secondary causes previously discarded). ALPL
genetic testing and a systematized questionnaire to retrieve demographic, clinical and laboratory data were
performed. Descriptive analysis and logistic regression models were employed to identify the clinical and laboratory
characteristics associated with ALPL variants.
Results: Forty subjects (47%) had a variant(s) in ALPL. With regard to clinical characteristics, the presence of an ALPL
variant was significantly associated only with musculoskeletal pain (OR: 7.6; 95% IC: 1.9–30.9). Nevertheless, a trend
to present more dental abnormalities (OR: 3.6; 95% IC: 0.9–13.4) was observed. Metatarsal stress fractures were also
more frequent (4 vs 0; p < 0.05) in this group. Regarding laboratory features, median ALP levels were lower in
subjects with ALPL variants (26 vs 29 IU/L; p < 0.005). Interestingly, the threshold of ALP levels < 25 IU/L showed a
specificity, positive predictive value and positive likelihood ratio of 97.8, 94.4% and 19.8 to detect a positive ALPL
test, respectively.
Conclusions: In subjects with persistent hypophosphatasaemia –secondary causes excluded– one out of two
presented ALPL variants. Musculoskeletal pain and ALP levels < 25 IU/L are associated with this variant(s). In this
scenario, ALP levels < 25 IU/L seem to be very useful to identify individuals with the presence of an ALPL variant.
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Background
Hypophosphatasia (HPP) is an inborn error of metabol-
ism characterized by low levels of serum alkaline phos-
phatase (ALP) caused by loss-of-function variants. This
results in variants in ALPL, located on chromosome
1p36.1-p34, which encodes the tissue-nonspecific alka-
line phosphatase [1, 2]. Impaired ALP activity can lead
to the extracellular accumulation of ALP-specific sub-
strates, such as inorganic pyrophosphate (PPi), a potent
inhibitor of bone and dental mineralization [3].
HPP is a rare disease with an estimated prevalence in
Europe of 1/300,000 in severe cases and of 1/6370 in
moderate cases [4]. HPP covers a wide spectrum of clin-
ical manifestations whose severity inversely correlates
with the age of onset [5, 6]. Clinical features range from
lethal phenotypes or rickets in early ages to musculo-
skeletal pain, chondrocalcinosis, calcific periarthritis or
fractures in adults [5, 7].
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The genetic background of subjects may impact the
clinical course of HPP: recessive inherited variants are
commonly associated with more severe manifestations,
while both autosomal dominant and recessive inherit-
ance may occur in milder forms [8]. Hence, efforts have
been made to identify ALPL disease-causing variants and
their pattern of inheritance. To date, more than 380
variants have been described [9]. In addition, a high
phenotypic variability within members of the same fam-
ily sharing the same disease causing variants has been
observed [8, 10].
The main biochemical hallmark of HPP is hypopho-
sphatasaemia; however, in clinical practice, low ALP levels
are often overlooked and their causes are not usually
investigated [6, 11], even when evaluating bone fragility.
This lack of clinical attention often leads to erroneous
diagnoses and prescription of contraindicated drugs in
HPP, such as antiresorptive agents [12, 13].
Scarce evidence exists about features that should signal
the potential association between hypophosphatasaemia
and HPP in adults. Previous studies have shown a pro-
longed delay in the diagnosis of HPP [5, 14, 15] and
access to the genetic testing is not always possible or
rapid testing may be required.
In this context, the aims of this study were to estimate
the prevalence of subjects with variants in ALPL among
those with persistent hypophosphatasaemia and to deter-
mine the clinical and laboratory features associated with
the presence of ALPL variants and their utility to identify
a positive genetic test in the diagnostic work-up of HPP.
Results
Study population
Out of 386,353 subjects, screened by enzyme assay, 231,
805 adults had at least two ALP measurements, of whom
427 exhibited persistent hypophosphatasaemia (i.e. ≥2
ALP values ≤35 IU/L and none > 45 IU/L). Thirty-one
subjects were excluded because of secondary causes of
low ALP levels (detailed in Fig. 1) and 13 because they
could not be contacted by telephone. A total of 383 indi-
viduals fulfilled the selection criteria and were contacted,
of whom 274 declined to participate. Finally, 109 sub-
jects were enrolled and 85 signed the informed consent
for the genetic testing. Study overview and selection
procedures are depicted in Fig. 1.
The prevalence of persistent hypophosphatasaemia in
adults of our clinical setting was 0.18% (see Fig. 1). Gen-
etic test was performed in 85 individuals: 39 (46%) dis-
played pathogenic (P) or likely pathogenic (LP) variants
in ALPL (positive genetic test: +GT group), 45 (53%) did
not show any P or LP variants (negative genetic test:
-GT group) and one subject had a variant of unknown
significance (VUS). Segregation analysis in the family of
this subject displaying a VUS could not be performed;
consequently, this case was excluded from further statis-
tical analysis.
Regarding the subjects who showed variants in ALPL,
75% (30/40) were heterozygous for a P variant, 20% (8/
40) for a LP variant, 2.5% (1/40) for a VUS, and one
patient (2.5%) diagnosed of infantile HPP harbored com-
pound heterozygous pathogenic variants. This patient had a
history of multiple recurrent fractures, while subjects dis-
playing variants in heterozygosity exhibited a less severe
phenotype. Nine subjects had variants previously associated
with odonto-HPP. We identified four variants previously un-
reported in the literature: two pathogenic variants [c.388_
389insG; p.(Val130Glyfs*6) and c.619G >C; p.(Gln207Glu)]
and two likely pathogenic variants [c.317A >G; p.(Gln10
6Arg) and c.547G >A; p.(Asp183Asn)]. The substitutions
p.(Gly112Arg), p.(Val128Met), p.(Glu291Lys) and p.(Thr11
5_Ala116dup) were each present in three subjects; the
disease-causing variants p.(Arg152Cys), p.(Asp183Asn), p.(A
sp378Gly), p.(Thr166Ile), p.(Gly491Arg) and p.(Glu191Lys)
in two subjects and the rest were observed in single subjects.
Thirty-four subjects (85%) had missense disease-causing var-
iants, three had duplications (7.5%) and the rest had dele-
tions, insertions or splice site mutations (one subject for
each group, respectively). Most of the variants were located
in exons 5,6 and 9, were predicted to have a damaging
effect in silico pathogenicity prediction tools and were
absent or existed at extremely low frequencies in gno-
mAD. Additional file 1: Table S1 summarizes the
complete list of ALPL variants and the clinical findings
associated to each of them.
Demographic characteristics of study participants are
shown in Table 1. Median (IQR) age was 45 (38–55)
years in the overall population. Compared with the -GT
group, the +GT group showed a lower percentage of
females and had a higher body mass index.
Clinical manifestations
Clinical features of +GT and –GT groups are detailed in
Table 2. In the univariable analysis, the presence of muscu-
loskeletal pain, premature tooth loss, dental abnormalities,
metatarsal stress fractures and history of orthopedic
surgery were significantly higher in the +GT group. While
metatarsal stress fractures were detected in four subjects in
the + GT group, no subject reported this type of fracture
in the -GT group.
Data from the knee and/or pelvis X-ray was available for
11 subjects: 5 in the +GT group and 6 in the -GT group.
Among them, two subjects in the former had radiographic
chondrocalcinosis signs (one of them with a previous diag-
nosis of pyrophosphate arthropathy), contrasting with a
negative previous history in the -GT group. A higher VAS
was observed in the +GT group [3 (2–5) vs 1 (0–5); p < 0.05]
although functional assessments, as measured by HAQ-DI
were comparable in the two genetic groups.
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Furthermore, regression models adjusted for pos-
sible confounders (age, sex and body mass index) were
employed to evaluate the association between clinical
manifestations and ALPL disease causing variants. The
results are shown in Table 3. The only significant as-
sociation with a positive genetic status was found for
the presence of musculoskeletal pain (OR: 7.6; 95% IC:
1.9–30.9). In addition, a trend was also detected for
dental abnormalities (OR: 3.6; 95% IC: 0.9–13.4). In
this respect, nine subjects carried variants associated
with odonto-HPP, of whom only five referred previous
dental problems. Metatarsal stress fractures could not
be analysed when adjusting for confounders because
of convergence problems.
In the +GT group, a median 19-year delay between
first signs or symptoms and diagnosis was observed, be-
ing the median (IQR) age at the onset of the symptoms
of 40.3 years (13.6–50.5) and at the diagnosis of 49.8
(37.2–63.3) years. Median diagnostic delay was 22.7
(19.6–34.6) for those who experienced a pediatric onset
(n = 9) and 11.9 (7–21.2) for those who did not report
symptoms before age 18 (n = 29). In terms of initial
Fig. 1 Flowchart describing screening and selection process. ALP = alkaline phosphatase; +GT and –GT refer to subjects with either presence or
absence of disease causing variants in ALPL, P = pathogenic; LP = likely pathogenic; VUS = Variant of unknown significance. *Two of the P
variants are present in one patient in compound heterozygosity
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HPP-associated symptoms, 8 subjects reported dental
problems at a median age at onset of 14.51 (7.7–19.5);
18, musculoskeletal symptoms at a median age at onset
of 43 (14.8–51.8) and 2 of them, kidney complications.
Laboratory findings
The biochemical profile of study participants is presented
in Table 4. ALP median (IQR) serum levels were signifi-
cantly lower in the +GT group compared to those in the –
GT group [26 IU/L (22–29) vs 29 IU/L (27–32), p < 0.005].
In contrast, median phosphate levels were significantly
higher in the +GT group compared with the –GT group [4
mg/dL (3.5–4.5) vs 3.4mg/dL (3.1–4.1), p < 0.05, respect-
ively). Eleven percent (5/44) of subjects, based on the avail-
able data, presented hyperphosphoremia (> 4.5mg/dL),
most (4/44) in the +GT group. Median calcium levels were
within the normal range, statistically comparable in both
groups, and hypercalcemia was not observed in subjects
using the available data. Levels of 24-h urinary calcium and
phosphate excretion did not differ between groups.
The utility of identifying the presence of ALPL variants
based on different ALP cut-off levels (20, 25, 30 and 35 IU/
L) was assessed (Table 4). The threshold of 25 IU/L served
as the best predictor of a positive ALPL genetic test in the
current study population. Of the 18 subjects with ALP levels
below 25 IU/L, 17 had a positive genetic test and only one a
negative result. The values for sensitivity, specificity, positive
and negative predictive value, and positive and negative
likelihood ratio for ALP levels below 25 IU/L were 43.6,
97.8, 94.4, 66.7%, 19.8 and 0.58, respectively (see Table 5).
Of the 65 subjects with ALP levels between 25 and 35
IU/L, we evaluated whether those clinical symptoms
potentially related to HPP could improve the detection
of a positive variant in our population. In the 36 subjects
who presented musculoskeletal pain, 15 (41.7%) displayed
a positive variant and 21 (58.3%), a negative genetic test.
Table 1 Demographic characteristics of participants, stratified by ALPL genetic test
+GT* (N = 39) –GT* (N = 45) Total (N = 84) p value
Median age (IQR), years 49 (37–63) 44 (38–48) 45 (38–55) 0.092
Female sex, n(%) 23 (59%) 38 (84.4%) 61 (72.6%) 0.009**
Race
Caucasian,n(%) 37 (94.8%) 45 (100.0%) 82 (97.6%) 0.3
Hispanoamerican, n(%) 1 (2.6%) 0 1 (1.2%)
Black,n(%) 1 (2.6%) 0 1 (1.2%)
Median BMI*(IQR), kg/m2 24.6 (23.1–28.8) 22.2 (20.4–24.3) 23.5 (21.3–26.6) 0.01**
*GT positive genetic test, −GT negative genetic test, BMI body mass index. **Significant statistical differences between groups
Table 2 Clinical manifestations of participants stratified by ALPL genetic testing
Clinical feature, n (%) +GT* (N = 39) –GT* (N = 45) Total (N = 84) p value
Musculoskeletal pain 31 (79.5%) 21 (46.7%) 52 (61.9%) 0.002**
Fractures
History of fractures 17 (43.6%) 15 (33.3%) 32 (38.1%) 0.334
Multiple fractures 2 (5.0%) 0 (0.0%) 2 (2.4%) 0.129
Peripheral fractures 18 (45.0%) 13 (28.9%) 31 (36.5%) 0.124
Metatarsal fractures 4 (10.0%) 0 4 (4.7%) 0.007**
Family history of fractures 6 (15.8%) 9 (20.0%) 15 (18.1%) 0.619
Orthopedic surgery 7 (18.4%) 2 (4.4%) 9 (10.8%) 0.041**
History of premature teeth loss 6 (15.4%) 1 (2.2%) 7 (8.3%) 0.029**
Dental abnormalities 12 (31.6%) 6 (13.3%) 18 (21.7%) 0.045**
Family history of dental problems 11 (35.5%) 14 (34.1%) 25 (34.7%) 0.906
Muscle weakness 6 (15.4%) 3 (6.7%) 9 (10.7%) 0.198
Calcific periarthritis 4 (10.3%) 3 (6.7%) 7 (8.3%) 0.553
Chondrocalcinosis 2 (5,1%) 0 2 (2,4%) 0.124
Median VAS* (IQR) 3 (2–5) 1 (0–5) 2 (0–5) 0.038**
Median HAQ-DI* (IQR) 0 (0–0.3) 0 (0–0.1) 0 (0–0.3) 0.872
*+ GT positive genetic test, −GT negative genetic test, VAS Visual Analog Scale, HAQ-DI Health Assessment Questionnaire-Disability Index. **Significant statistical
differences between groups
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In addition, 12 subjects reported dental abnormalities (half
having an ALPL variant) and two individuals diagnosed
with HPP experienced metatarsal fractures. The specificity
and positive predictive value for musculoskeletal pain in
this group of subjects were 52.3 and 41.7%, respectively
and 86.4 and 50% for dental abnormalities; thus, the
discriminative power did not increase (Additional file 2:
Table S2).
Discussion
Persistently low ALP levels can stem from different eti-
ologies, including HPP. Characterization of the HPP
spectrum in adults, which is generally characterized by
milder symptoms than in pediatric-onset HPP, is crucial
for the correct management and treatment of the dis-
ease. In addition, an accurate clinical and biochemical
characterization can help distinguish between congenital
HPP and secondary hypophosphatasaemia.
In this context, the results of our study are very rele-
vant. Besides establishing the prevalence of an ALPL
disease-causing variant in adult subjects with persistent
hypophosphatasaemia, this is the first study utilizing a
common biomarker to identify a positive genetic ALPL
test.
The prevalence of persistent hypophosphatasaemia in
adults of our clinical setting was 0.18%, which is in agree-
ment with two studies, one conducted in a large rural
multispecialty clinic population in the USA (prevalence
0.06%) [11] and another in a French tertiary hospital
(0.13%) [6]. In our cohort, the subjects included were
mainly Caucasians, aged around 50 years and predomin-
antly female, which was congruent with other recent stud-
ies [5, 16, 17]. Furthermore, the estimated prevalence of
ALPL disease-causing variants in these subjects with per-
sistent hypophosphatasaemia was 47%. This means that
one out of two subjects with persistent hypophosphatasae-
mia (secondary causes discarded) had HPP, which is in
accordance with the study of Riancho-Zarrabeitia and co-
workers [18]. More recently, the study of Mckiernan et al.
[19] found a higher proportion of subjects with ALPL
disease-causing variants (84%), most likely because a more
stringent definition of hypophosphatasaemia was used.
We identified four previously unreported variants based
on the American College of Medical Genetics and Gen-
omics (ACMG) classification criteria [20]. The majority of
the variants were missense in nature and were located in
exons five, six and nine, as has been commonly observed
in public databases and previous reports [9, 18].
According to our results, approximately 50% of per-
sistently low APL levels signify a different underlying
etiology than HPP. Therefore, genetic confirmation by
ALPL genetic testing is required. Nevertheless, in clinical
practice, access to such testing is not always available or
rapid testing is required. Therefore, it would be very use-
ful to identify the clinical and routine biochemical char-
acteristics of the disease and its predictive value for a
proper and early diagnosis, in order to avoid erroneous
therapeutic decisions.
Based on the results of this study, neither single nor com-
bined clinical manifestation are useful enough for
Table 3 Results of the logistic regression model adjusted for
possible confounders (age, sex and BMI) showing the
association between the clinical features and genetic status
Clinical feature Odds Ratio 95% IC p value
Musculoskeletal pain 7.6 1.9–30.9 0.005**
Peripheral fractures 1.2 0.4–4 0.769
Family history of fractures 0.4 0.06–2.2 0.273
Orthopedic surgery 3.7 0.5–27.1 0.199
History of premature tooth loss 1.7 0.1–21.9 0.673
Dental abnormalities 3.6 0.9–13.4 0.053
Family history of dental problems 0.7 0.2–2.3 0.513
Muscle weakness 3.1 0.4–27.6 0.309
Calcific periarthritis 1.5 0.2–9.9 0.680
**Significant statistical differences between groups
Table 4 Biochemical variables of study participants, stratified by genetic test results
Biochemical variables, [Median (IQR)] +GT* (N = 39) –GT* (N = 45) Total (N = 84) p value
ALP*, IU/L (N = 39, 45, 84) 26 (22–29) 29 (27–32) 28 (25–31) 0.001**
< 20 IU/L 6 (15%) 0 (0%) 6 (7.1%)
< 25 IU/L 17 (44%) 1 (2%) 18 (21%)
< 30 IU/L 32 (82%) 25 (56%) 57 (68%)
< 35 IU/L 38 (97%) 43 (96%) 81 (96%)
Calcium, mg/dL (N = 34, 44, 78) 9.4 (9.1–9.7) 9.2 (9.1–9.4) 9.3 (9.1–9.6) 0.251
Phosphate, mg/dL (N = 20,24,44) 4 (3.5–4.5) 3.4 (3.1–4.1) 3.6 (3.2–4.3) 0.016**
Creatinine, mg/dL (N = 36, 39,75) 0.91 (0.9–1) 0.9 (0.8–1) 0.9 (0.9–1) 0.053
Urinary calcium excretion, mg/24 h (N = 4, 1, 5) 84.5 (22.6–98) 123 (123–123) 89 (41.7–112) 0.400
Urinary phosphate excretion, mg/24 h (N = 3, 0, 3) 35 (32.6) – 35 (32.6) –
*GT positive genetic test, −GT negative genetic test, ALP Alkaline phosphatase. **Significant statistical differences between groups
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identifying the presence of an ALPL variant. In contrast,
ALP levels seem to be discriminative enough for this pur-
pose. ALP levels below 25 IU/L showed a high specificity
(97.8%), positive predictive value (94.4%) and positive likeli-
hood ratio (19.8). Consequently, in the presence of symp-
toms potentially related to HPP and biochemical
abnormalities, specific ALP cut-off levels could help diag-
nostic strategies, especially when genetic testing is not avail-
able. If these results are confirmed in other populations,
these key findings could prove very useful in clinical
practice.
With regards to clinical features, only the presence of mus-
culoskeletal pain was significantly and strongly associated
with a positive genetic ALPL status. Previous publications
also showed a high incidence (41–95%) of musculoskeletal
pain in subjects with HPP [5, 15–17]. Indeed, Shapiro et al.
recently described musculoskeletal pain attributable to HPP
requiring pain medications, such as opioids, as one of the
scenarios necessitating treatment with enzyme replacement
[21]. However, given the high prevalence of pain in the over-
all population with hypophosphataseamia, the etiology and
characteristics of pain in HPP should be characterized before
therapeutic intervention. Metatarsal stress fractures were also
more frequent in individuals with ALPL disease-causing vari-
ants. In a recent publication, metatarsal fractures reached a
prevalence of 21% and were considered typical of HPP [16].
The number of subjects presenting this feature was limited
and did not allow for any definitive conclusions. Neverthe-
less, it was the only distinctive clinical symptom related to a
positive genetic result when ALP levels were above 25 IU/L.
On the other hand, to implement strategies that will
enable an early detection of the disease is mandatory. In
our study, a significant 19-year delay was observed,
which is in accordance with the global HPP Registry, the
largest observational study including real-world data
cases [15]. Our study aimed to highlight the distinct
clinical characteristics of two groups of subjects with the
same biochemical abnormality but with a different gen-
etic status. Clarifying this aspect is an important issue
from the diagnostic point of view, given the high clin-
ical variability of the disease [22], the evidence of
normal substrates in some adults carrying a defective
ALPL allele and the limitations of conventional gen-
etic studies [18, 23].
The main weaknesses of our study are the lack of
pediatric medical histories, the use of a clinical question-
naire for identifying clinical symptoms and limited data
available regarding certain variables, such as radiographic
records. As a limitation, the design of the study does not
allow us to establish a definitive clinical diagnosis of HPP:
although a detailed questionnaire was designed for the
evaluation of subjects included, a complete visit and com-
plementary tests targeted to study clinical features or
laboratory abnormalities were not performed, so that
some subjects with variants in ALPL could be carriers.
Furthermore, ALP substrates and the analysis of the dom-
inant negative effect of the variants have not been per-
formed due to limitations in their determination.
The main strengths are the thorough analysis of med-
ical records, which yielded a considerably large sample
size for a rare disease, the integration of data across a
wide range of variables, the analysis of information ob-
tained through a detailed clinical questionnaire and the
genetic analysis encompassing this large population. In
addition, to the best of our knowledge, this is the first
time that ALP cut-off levels are used to identify a
positive ALPL genetic test, although these results need
further investigation.
Conclusions
In subjects with persistent hypophosphatasaemia, one
out of two individuals with primary low ALP levels, pre-
sented an ALPL disease-causing variant. It is imperative
that the clinical and biochemical characteristics and its
predictive value are defined if early diagnoses are to be
obtained and erroneous therapeutic decisions avoided.
Musculoskeletal pain and ALP levels below or equal to
25 IU/L are associated with a positive result in ALPL
genetic testing. In this scenario, ALP levels below this
threshold seem to be very useful for predicting the pres-
ence of ALPL disease-causing variant. If confirmed in
other populations, these key findings can be useful in
clinical practice. Prospective studies evaluating these
findings and establishing the natural evolution of HPP
will definitely enable a comprehensive determination of
the disease’s complete clinical spectrum in adults.
Methods
Study population and design
This cross-sectional study was performed at La Paz Uni-
versity Hospital (Madrid, Spain). The study adhered to
the tenets of the Declaration of Helsinki and approval
was obtained from its ethics committee. Each subject
provided written informed consent prior to inclusion.
First, 1,536,711 laboratory records including ALP serum
levels values from 386,353 subjects were screened to iden-
tify abnormally low ALP results. These values were re-
corded in the biochemical database of the hospital from
Table 5 Diagnostic utility measures for serum ALP level
thresholds
ALPa levels Sensitivity Especificity PPV NVP +LR -LR
< 20 IU/L 15.4% 100% 100% 57.7% Infinity 0.85
< 25 IU/L 43.6% 97.8% 94.4% 66.7% 19.8 0.58
< 30 IU/L 82.1% 44.4% 56.1% 74.1% 1.48 0.4
< 35 IU/L 97.4% 4.4% 46.9% 66.7% 1.02 0.59
PPV positive predictive value, NPV negative predictive value, LR likelihood
ratio, ALP Alkaline phosphatase
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2009 to 2015. The main criteria for inclusion were: adults
aged 18 years or older with persistent hypophosphatasae-
mia, defined as ≥2 ALP measurements below or equal to
35 IU/L. Subjects were excluded if ≥1 ALP values were
above 45 IU/L (lower limit for adults), or if clinical records
revealed secondary underlying causes of hypophosphata-
saemia, such as cancer or chemotherapy, adynamic renal
osteodystrophy, severe hypothyroidism, Cushing’s disease,
Wilson’s disease, nutritional deficiencies, hypomagnes-
emia, hypozincemia, myocardial infarction, sepsis, major
trauma or surgery, massive transfusions and clofibrate
therapy among others [11].
Collected data
Eligible subjects completed a questionnaire to report
family or personal history of musculoskeletal pain,
muscle weakness, fractures, premature dental loss and
previous orthopedic surgery, among other clinical fea-
tures classically associated with HPP. Additionally, radio-
graphic data were retrieved from medical records.
Musculoskeletal pain was considered when symptoms
were recurring or chronic (> 6 months) and not when
transient and muscle weakness was defined by a chronic
subjective perception of a decrease in muscle strength,
but no physical examination was performed. Dental ab-
normalities were defined as tooth shape abnormalities,
structure and colour abnormalities of enamel or dentin,
thin enamel, late teeth eruption or severe/recurrent cav-
ities and early loss of permanent teeth was defined as
the loss of several teeth or extraction (> 10) due to tooth
abnormalities in the past, prior to the age of 50. In terms
of fractures, peripheral traumatic and fragility ones were
evaluated as were stress metatarsal and atypical frac-
tures. Multiple fractures were defined as more than
three. Chondrocalcinosis and calcific periarthritis were
considered when the subject had a previous diagnosis or
if a prior imaging test confirmed the diagnosis. Subjects
were required to grade their pain on a 100 mm visual
analog scale (VAS) and to complete the Health Assess-
ment Questionnaire-Disability Index (HAQ-DI). Individ-
uals were requested to provide a blood sample for the
genetic analysis.
Laboratory methods
Between 2009 and 2013, the University La Paz Hospital
Laboratory utilized an Olympus 5400 analyzer (Beckman
Coulter) to measure serum ALP activity. In February
2014, it switched to Siemens Healthineers (Advia 2400
chemistry system) and clinically acceptable correlation
and comparison was demonstrated between the two de-
vices (internal Laboratory data available). Both methods
measure ALP activity by a kinetic rate method in which p-
nitrophenyl phosphate (a colourless organic phosphate
ester substrate) is hydrolyzed by ALP to the yellow-
coloured product pnitrophenol and phosphate at pH 10,3.
Enzymatic activity of ALP is directly proportional to
changes in absorbance at 410 nm. The normal adult’s
range is 45 to 116 IU/L.
Genetic analysis
Genomic DNA was extracted from peripheral blood with
a Chemagic Blood kit (Perkin Elmer, Waltham, MA) and
the screening of the exons and intron/exon boundaries of
ALPL (NM_000478.4) was performed by Sanger sequen-
cing. In silico pathogenicity prediction and control popu-
lation frequency analysis were assessed using Alamut V2.6
software (Interactive Biosoftware Rouen, France), Var-
some (https://varsome.com/), CADD software (http://
cadd.gs.washington.edu) and Silvent et al. criteria [24].
The allelic frequencies were determined using gnomAD
(http://gnomad.broadinstitute.org/) and the in silico tools
included CADD V1.3, DANN, SIFT, Polyphen, Mutation-
Tester, Mutation assessor, FATHM and SpliceSiteFinder-
like, MaxEntScan, NNSPLICE, GeneSplicer. The ALPL
disease-causing variants database (http://www.se-sep.uvsq.
fr/03_hypo_mutations.php) was also consulted to obtain
up-to-date information about the genetic variants in-
cluded in our study (Additional file 1: Table S1) already
identified [25–36]. Variants were classified according to
the American College of Medical Genetics and Genomics
(ACMG) standards and guidelines [20].
Statistical analysis
First, descriptive analysis was employed to determine the
prevalence of ALPL variants among subjects with persistent
hypophosphatasaemia and to compare clinical and labora-
tory characteristics between individuals with and without
ALPL variants. Continuous variables were described as me-
dian (interquartile range –IQR-) and categorical variables
as an absolute number and relative percentage. Compari-
sons between two independent groups for continuous
variables were performed using the Student’s t-test for un-
paired data if normally distributed, or a Mann-Whitney U
test when not. Statistical significance difference between
groups for categorical variables was calculated using the
Chi-square test or the Fisher’s exact test, as appropriate.
Logistic regression models adjusted for confounders were
employed to investigate the association between clin-
ical and laboratory characteristics and the genetic sta-
tus. Finally, diagnostic utility measures (sensitivity,
specificity, positive and negative predictive value and
positive and negative likelihood ratio) to predict the
likelihood of having an ALPL variant were calculated.
The level of statistical significance was set at p < 0.05.
Statistical analyses were performed using the IBM
SPSS Statistics 23.0 for Windows.
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13023-020-1315-y.
Additional file 1: Table S1. List of subjects displaying ALPL disease
causing variants observed in the cohort according to the transcript
NM_000478.4, clinical features associated and family history available.
Additional file 2: Table S2. Diagnostic utility measures for each of the
symptoms combined with ALP levels between 25 and 35 IU/L.
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